Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ..
BACKGROUND: The susceptibility of patients with rheumatic diseases and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown.
METHODS: We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with severe acute respiratory syndrome coronavirus 2-positive PCR tests performed in the hospital to the same reference populations. Rates of PCR+ confirmed COVID-19 were compared among groups.
RESULTS: Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Patients with systemic autoimmune or immune-mediated disease (AI/IMID) showed a significant increase, whereas patients with inflammatory arthritis (IA) or systemic lupus erythematosus did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. Patients with IA on targeted-synthetic or biological disease-modifying antirheumatic drugs (DMARDs), but not those on conventional-synthetic DMARDs, had a greater prevalence despite a similar age distribution.
CONCLUSION: Patients with AI/IMID show a variable risk of hospital-diagnosed COVID-19. Interplay of ageing, therapies and disease-specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyse the specific factors involved in COVID-19 susceptibility.
| Errataetall: |
CommentIn: Ann Rheum Dis. 2022 Dec;81(12):e243. - PMID 32978235 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 79(2020), 9 vom: 12. Sept., Seite 1170-1173 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pablos, Jose L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic Agents |
|---|
| Anmerkungen: |
Date Completed 08.09.2020 Date Revised 29.08.2023 published: Print-Electronic CommentIn: Ann Rheum Dis. 2022 Dec;81(12):e243. - PMID 32978235 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2020-217763 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311118860 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311118860 | ||
| 003 | DE-627 | ||
| 005 | 20231225141555.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2020-217763 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1037.xml |
| 035 | |a (DE-627)NLM311118860 | ||
| 035 | |a (NLM)32532753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pablos, Jose L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2020 | ||
| 500 | |a Date Revised 29.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ann Rheum Dis. 2022 Dec;81(12):e243. - PMID 32978235 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a BACKGROUND: The susceptibility of patients with rheumatic diseases and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown | ||
| 520 | |a METHODS: We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with severe acute respiratory syndrome coronavirus 2-positive PCR tests performed in the hospital to the same reference populations. Rates of PCR+ confirmed COVID-19 were compared among groups | ||
| 520 | |a RESULTS: Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Patients with systemic autoimmune or immune-mediated disease (AI/IMID) showed a significant increase, whereas patients with inflammatory arthritis (IA) or systemic lupus erythematosus did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. Patients with IA on targeted-synthetic or biological disease-modifying antirheumatic drugs (DMARDs), but not those on conventional-synthetic DMARDs, had a greater prevalence despite a similar age distribution | ||
| 520 | |a CONCLUSION: Patients with AI/IMID show a variable risk of hospital-diagnosed COVID-19. Interplay of ageing, therapies and disease-specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyse the specific factors involved in COVID-19 susceptibility | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a arthritis | |
| 650 | 4 | |a autoimmune diseases | |
| 650 | 4 | |a biological therapy | |
| 650 | 4 | |a epidemiology | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 700 | 1 | |a Abasolo, Lydia |e verfasserin |4 aut | |
| 700 | 1 | |a Alvaro-Gracia, Jose M |e verfasserin |4 aut | |
| 700 | 1 | |a Blanco, Francisco J |e verfasserin |4 aut | |
| 700 | 1 | |a Blanco, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Castrejón, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Fernandez, David |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Gutierrez, Benjamín |e verfasserin |4 aut | |
| 700 | 1 | |a Galindo-Izquierdo, María |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Gay, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a Manrique-Arija, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Mena Vázquez, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Mera Varela, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Retuerto, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Seijas-Lopez, Alvaro |e verfasserin |4 aut | |
| 700 | 0 | |a RIER investigators group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 79(2020), 9 vom: 12. Sept., Seite 1170-1173 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2020 |g number:9 |g day:12 |g month:09 |g pages:1170-1173 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2020-217763 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2020 |e 9 |b 12 |c 09 |h 1170-1173 | ||